Skip to main content

Volume 3 Supplement 2

30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015)

Predicting CD137 upregulation on NK cells in patients receiving monoclonal antibody therapy


Monoclonal antibody (mAb) therapy-has changed the natural history of patients with B cell lymphomas, breast cancer, and head and neck cancers. However, response rates are suboptimal, highlighting the need to enhance mAb activity. Combining a tumor targeting mAb with a second antibody that activates natural killer (NK) cells may improve the therapeutic effects of mAbs. Engagement of the Fc receptor (FcR) on NK cells by mAbs coating tumor cells has been previously shown to enhance their expression of CD137 [13]. We conducted preliminary analyses as a first step toward developing a nomogram to predict CD137 up-regulation following therapy with mAb.


Patient tumor and immune characteristics were collected from patients with Non-Hodgkin's lymphoma, breast cancer, and head and neck cancers receiving mAb therapy as part of clinical trials. CD137 expression pre- and post-mAb therapy was assessed by mass cytometry time of flight (CyTOF) analysis. We examined the difference (post-pre mAB therapy) in CD137 expression for each cancer type. Specifically, we applied multivariate lasso regression tools and used classification and regression trees (CART) to predict post-CD137 expression, separately for each cancer type.


We analyzed data from 62 patients with breast cancer, 46 with head/neck cancer and 91 with Non-Hodgkin's lymphoma. The difference (post-pre) in CD137 expression values was significantly different for each cancer type (mean (SD): Breast: 6.6 (6.5); Head/Neck: 11.0 (7.0); NHL: 7.5 (7.1), p


Our preliminary results suggest that FcR polymorphism, pre-treatment expression levels of CD137 and age are significant predictors of CD137 uptake in patients. Further work validating our models will provide the opportunity to develop a nomogram that may be used to individualize this therapeutic approach for patients.


  1. 1.

    Kohrt HE, Houot R, Goldstein MJ, Weiskopf K, Alizadeh AA, Brody J, et al: CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood. 2011, 117 (8): 2423-2432.

    PubMed  CAS  PubMed Central  Article  Google Scholar 

  2. 2.

    Kohrt HE, Houot R, Weiskopf K, Goldstein MJ, Scheeren F, Czerwinski D, et al: Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. J Clin Invest. 2012, 122 (3): 1066-1067.

    PubMed  CAS  PubMed Central  Article  Google Scholar 

  3. 3.

    Kohrt HE, Colevas AD, Houot R, Weiskopf K, Goldstein MJ, Lund P, et al: Targeting CD137 enhances the efficacy of cetuximab. J Clin Invest. 2014, 124 (6): 2668-2682.

    PubMed  CAS  PubMed Central  Article  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Holbrook E Kohrt.

Rights and permissions

Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.

The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this licence, visit

The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Makkouk, A., Sundaram, V., Desai, M. et al. Predicting CD137 upregulation on NK cells in patients receiving monoclonal antibody therapy. j. immunotherapy cancer 3, P98 (2015).

Download citation

  • Published:

  • DOI:


  • Breast Cancer
  • Natural Killer Cell
  • Neck Cancer
  • CD137 Expression
  • Cancer Type